Arlington Capital Management Inc. Purchases Shares of 9,520 Novo Nordisk A/S (NYSE:NVO)

Arlington Capital Management Inc. acquired a new position in Novo Nordisk A/S (NYSE:NVO) during the 4th quarter, Holdings Channel reports. The firm acquired 9,520 shares of the company’s stock, valued at approximately $985,000.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Jennison Associates LLC grew its position in shares of Novo Nordisk A/S by 100.3% during the 3rd quarter. Jennison Associates LLC now owns 23,419,405 shares of the company’s stock valued at $2,129,761,000 after acquiring an additional 11,727,507 shares during the period. Polen Capital Management LLC purchased a new position in Novo Nordisk A/S during the third quarter valued at $718,995,000. FMR LLC increased its position in Novo Nordisk A/S by 122.7% in the third quarter. FMR LLC now owns 12,077,501 shares of the company’s stock worth $1,098,328,000 after buying an additional 6,654,614 shares in the last quarter. Morgan Stanley raised its stake in shares of Novo Nordisk A/S by 96.5% in the third quarter. Morgan Stanley now owns 9,215,098 shares of the company’s stock worth $838,021,000 after buying an additional 4,526,199 shares during the period. Finally, Loomis Sayles & Co. L P lifted its position in shares of Novo Nordisk A/S by 91.7% during the 3rd quarter. Loomis Sayles & Co. L P now owns 9,097,808 shares of the company’s stock valued at $827,354,000 after buying an additional 4,350,862 shares in the last quarter. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Price Performance

NVO traded up $1.24 during trading on Thursday, hitting $127.93. 765,103 shares of the company traded hands, compared to its average volume of 4,786,642. The company has a market cap of $574.09 billion, a PE ratio of 43.69, a P/E/G ratio of 1.93 and a beta of 0.43. Novo Nordisk A/S has a 1 year low of $75.56 and a 1 year high of $138.28. The company has a current ratio of 0.70, a quick ratio of 0.50 and a debt-to-equity ratio of 0.17. The stock’s 50-day simple moving average is $127.33 and its two-hundred day simple moving average is $113.50.

Wall Street Analyst Weigh In

Several research firms recently issued reports on NVO. UBS Group started coverage on shares of Novo Nordisk A/S in a report on Tuesday, January 16th. They issued a “neutral” rating for the company. Morgan Stanley started coverage on shares of Novo Nordisk A/S in a research report on Tuesday, January 23rd. They set an “overweight” rating and a $120.00 price objective on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $160.00 target price on shares of Novo Nordisk A/S in a report on Thursday, April 18th. Finally, BMO Capital Markets began coverage on Novo Nordisk A/S in a report on Friday, April 12th. They set an “outperform” rating and a $163.00 price target on the stock. Two analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $133.60.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.